Showing 3131-3140 of 5621 results for "".
- Low Vision Resources and Rehabilitation for Retinal Degeneration Patients: A Webinar to Discuss Critical Needs and Opportunitieshttps://modernod.com/news/low-vision-resources-and-rehabilitation-for-retinal-degeneration-patients-a-webinar-to-discuss-critical-needs-and-opportunities/2478431/The Foundation Fighting Blindness is hosting a low vision webinar to inform eye care professionals about the many opportunities to greatly enhance the quality of life, and provide hope, for their retinal disease patients. The interactive webinar is appropriate for all eye care professional
- GSK, Vir Biotechnology Move Anti-SARS-CoV-2 Monoclonal Antibody Into Phase 3https://modernod.com/news/gsk-vir-biotechnology-move-anti-sars-cov-2-monoclonal-antibody-into-phase-3/2478385/GlaxoSmithKline and partner Vir Biotechnology announced that the COMET-ICE study evaluating VIR-7831 as an early treatment for COVID-19 patients deemed to be at high risk of hospitalization will proceed into phase 3 testing, with preliminary results coming possibly before the end of this year. Th
- Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopiahttps://modernod.com/news/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/2478356/Orasis Pharmaceuticals announced the closing of a $30 million Series C financing. Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia sympto
- Outlook Therapeutics Provides Update on First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degenerationhttps://modernod.com/news/outlook-therapeutics-provides-update-on-first-approved-ophthalmic-formulation-of-bevacizumab-vikg-for-advanced-macular-degeneration/2478349/Outlook Therapeutics announced progress on its phase 3 clinical program for the first FDA-approved ophthalmic formulation of bevacizumab-vikg (Lytenava) for use in retinal indications (known as ONS-5010 for use in retinal indications). Outlook plans the commercial launch of ONS-5010 in 202
- Employers Will Need to Respond Carefully Amid Roller Coaster of Health Costs During COVID-19https://modernod.com/news/employers-will-need-to-respond-carefully-amid-roller-coaster-of-health-costs-during-covid-19/2478345/Employers will likely see drops in year-over-year medical costs in 2020 after large numbers of employees deferred healthcare services due to the COVID-19 pandemic, according to a FierceHealthcare report. Despite the significant drop in the use of healthcare services in 2020, employer heal
- KKR to Acquire 1-800 Contacts from AEA Investorshttps://modernod.com/news/kkr-to-acquire-1-800-contacts-from-aea-investors/2478313/1-800 Contacts, the largest retailer of contact lenses in the US, announced a definitive agreement under which global investment firm KKR will acquire the company from AEA Investors. Financial terms of the transaction were not disclosed. “1-800 Contacts was founded 25 years ago to o
- Orbis International Announces New CEO & Presidenthttps://modernod.com/news/orbis-international-announces-new-ceo-president/2478251/Orbis International announced the appointment of Derek Hodkey as the organization’s new CEO and President, with immediate effect, following the retirement of Bob Ranck, who led Orbis for over 4 years.
- COVID-19 Vaccine Developers Seek to Reassure Public Over Safetyhttps://modernod.com/news/covid-19-vaccine-developers-seek-to-reassure-public-over-safety/2478249/Sources suggested that a number of drugmakers, including GlaxoSmithKline, Johnson & Johnson and Pfizer, are planning to release a statement outlining their commitment to only seek FDA approval of a vaccine against COVID-19 if it is supported by extensive safety and efficacy data. The move is
- Saliva COVID-19 Test as Good as, Perhaps Beats, Nasal Swab: Studyhttps://modernod.com/news/saliva-covid-19-test-as-good-as-perhaps-beats-nasal-swab-study/2478248/A COVID-19 saliva test protocol developed by researchers at Yale University appeared to perform at least as well as nasal swabs in a study of hospital patients, a finding that may help encourage more frequent use of self-collected samples, according to a Medscape
- Analysis Finds Corticosteroids Cut Risk of Death in Critically Ill COVID-19 Patientshttps://modernod.com/news/analysis-finds-corticosteroids-cut-risk-of-death-in-critically-ill-covid-19-patients/2478240/Results of a meta-analysis published Wednesday in JAMA suggest that the use of systemic corticosteroids in critically ill patients with COVID-19 is associated with lower 28-day all-cause mortality compared to usual care or placebo. Study author Jonathan Sterne noted that the benefit was